Centre asks Serum Institute and Bharat Biotech to lower prices of COVID-19 vaccines
The decision comes after many state governments have objected to different prices of the vaccines, with Delhi Chief Minister Arvind Kejriwal saying this is not time for 'profiteering'
Representational image. AP
New Delhi: The central government on Monday asked the Serum Institute and Bharat Biotech to lower the prices of their COVID-19
vaccines amid criticism from various states who objected to profiteering during such a major crisis.
The issue of vaccine pricing was discussed at a meeting chaired by Cabinet Secretary Rajiv Gauba. Now the two companies are expected to come up with revised pricing for their vaccines.
The Hyderabad-based Bharat Biotech has fixed the price of its COVID-19 vaccine, Covaxin, at Rs 600 per dose for state governments and at Rs 1,200 per dose for private hospitals.
The Pune-based Serum Institute of India (SII), the world's largest vaccine maker in terms of volume, has announced a price of Rs 400 per dose for its COVID-19 vaccine, 'Covishield', for state governments and Rs 600 per dose for private hospitals.
Both vaccines are available to the central government at a rate of Rs 150 per dose.
Many states have objected to different prices of the vaccines, with Delhi Chief Minister Arvind Kejriwal saying this is not time for profiteering.
India has announced the expansion of its COVID-19 vaccination drive by allowing its large 18-plus population to get inoculated from May 1.
also read
Centre should follow global example and make COVID vaccine free for all, says economist Ramakumar
The economist's comments comes in the backdrop of the Serum Institute of India’s hiking the price of its COVISHIELD vaccine. The Centre, meanwhile, has asked both SII and Bharat Biotech to lower the prices of their vaccines.
COVID-19 oxygen crisis: MHA directs states, UTs to not impose restrictions on movement of medical oxygen
The order also said that it has accepted the EG-II's recommendation to prohibit the supply of oxygen for industrial purposes by manufacturers and suppliers from 22 April with the exception of nine specified industries
COVID is a 'mild disease', less than 5% of patients need ventilator, says AIIMS chief Randeep Guleria
Speaking at a press conference in Delhi, the AIIMS director, appealing to the public not to hoard Remdesevir or oxygen cylinders at home, said 85 to 90 percent of people get only mild coronavirus infections